Business Development
Out Licensing
Lipocine is open to entertaining partnering discussions on our pipeline assets in various stages of development with a leading pharma company with infrastructure, expertise and presence in major markets or planning to maximize the global potential for the applicable therapeutic category.
Oral testosterone undecanoate (TLANDO® in U.S.) is our commercial product partnered in various territories.
Partnered Markets | Partners | Brand | Use |
|---|---|---|---|
USA | Verity Pharma | TLANDO® | Testosterone replacement therapy |
Canada | Verity Pharma | TLANDO® | Testosterone replacement therapy |
South Korea | SPC | TBD | Testosterone replacement therapy |
Brazil | Aché Laboratórios Farmacêuitcos S.A | TBD | Testosterone replacement therapy |
Gulf Cooperation Council
(GCC): Saudi Arabia, Kuwait,
the United Arab
Emirates (UAE), Qatar, Bahrain,
and Oman | Pharmalink | TBD | Testosterone replacement therapy |
In Licensing
Lipocine is looking for innovative products that will strengthen our metabolic and neuroendrocrine disorder treatment portfolio. These products can be in various development phases.